XSHE
000650
Market cap1.08bUSD
Oct 09, Last price
5.29CNY
1D
1.54%
1Q
0.57%
Jan 2017
-24.96%
Name
Renhe Pharmacy Co.
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Renhe Pharmacy Co., Ltd. is a pharmaceutical enterprise engaged in the manufacturing and distribution of a wide array of products. Its diverse portfolio includes both traditional Chinese and modern Western medicines, their essential raw materials, and various health and wellness items. These offerings are presented in numerous forms, such as oral solid preparations (e.g., tablets, capsules), liquid medications, large and small volume injectable solutions, topical treatments like lotions, liniments, and ointments, as well as suppositories and other health-related product formats. The company, which was established in 1996, maintains its corporate headquarters in Nanchang, China.
Key people
Zhenglian Xiao
Vice Chairman of the Board, Acting General Manager · since 2013
Wei Zhang
General Manager, Director · since 2013
Zhen Wang
Deputy General Manager · since 2017
Ziqiang Zhang
Deputy General Manager · since 2012
Feng Jiang
Secretary of the Board, Director · since 2010
Qiang Mei
Chairman of the Board · since 2013
Qiulin Peng
Chief Financial Officer, Director · since 2010
Independent Director · since 2013
Independent Director · since 2013
Independent Director · since 2013
IPO date
Dec 10, 1996
Employees
Domiciled in
CN
Incorporated in
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||